About Ypsilon Pharma
Ypsilon Pharma is a company based in Amsterdam (Netherlands) founded in 2014 by Taimaz Kianersi. It operates as a B2B. Ypsilon Pharma operates in a competitive market with competitors including Almac Group, Indoco Remedies, Concord Biotech, Nuritas and BDR Pharmaceuticals Internationals, among others.
- Headquarter Amsterdam, Netherlands
- Founders Taimaz Kianersi
- SectorsHealthcare
- Website ypsilonpharma.com
People of Ypsilon Pharma
1 people are tracked at Ypsilon Pharma (1 in leadership).
| Name | Role | Group |
|---|---|---|
Taimaz Kianersi | Founder, CEO | Leadership |
Complete people profiles for Ypsilon Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of Ypsilon Pharma
Ypsilon Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Almac Group, Indoco Remedies, Concord Biotech, Nuritas and BDR Pharmaceuticals Internationals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| almacgroup.com | 2001 | Craigavon, United Kingdom | $338.8M | 2,109 | Integrated CDMO services for biopharma R&D and manufacturing are offered. | |
| indoco.com | 1947 | Mumbai, India | – | 6,291 | APIs manufacturing and formulation services are provided in therapeutic segments. | |
| concordbiotech.com | 2000 | Ahmedabad, India | – | 1,598 | APIs and enzymes are manufactured through fermentation by the CDMO. | |
| nuritas.com | 2014 | Dublin, Ireland | $112.73M | – | Developer of natural active ingredients with scientifically proven health benefits | |
| bdrpharma.com | 2003 | Mumbai, India | $88.16M | 1,864 | APIs and finished products are developed and manufactured. | |
| aurobindo.com | 1986 | Hyderabad, India | – | 1,010 | Generic biocatalytic solutions are provided for pharmaceutical applications. | |
| asymchem.com | 1995 | Morrisville, United States | – | 48 | APIs and peptides are developed and manufactured by Asymchem. | |
| seqens.com | 2003 | Ecully, France | – | 44 | Contract manufacturing services for small molecules and peptides are provided. | |
| continuuspharma.com | 2012 | Woburn, United States | $7.73M | 47 | MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development | |
| brightseedbio.com | 2018 | San Francisco, United States | $120M | 48 | Plant bio-actives for human health are discovered via AI platform. |
Detailed competitors of Ypsilon Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Ypsilon Pharma
10 companies that operate in the same segment as Ypsilon Pharma (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Ypsilon Pharma
Ypsilon Pharma was founded in 2014.
Ypsilon Pharma is headquartered in Amsterdam, Netherlands.
Taimaz Kianersi is the current CEO of Ypsilon Pharma. They have also founded this company.
Ypsilon Pharma, led by Taimaz Kianersi as Founder, CEO, specializes in providing healthcare solutions, producing pharmaceutical products, drug manufacturing, and api and formulations. Manufactures high-quality APIs, formulations, and food supplements. The team drives innovation, quality service, and sustainable practices to achieve excellence and client satisfaction.
Ypsilon Pharma's top competitors include Concord Biotech, Nuritas and BDR Pharmaceuticals Internationals.